{"transactions":[{"id":1676663,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-18T18:18:45.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":15907,"price":19.65,"value":312572.55,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":377542,"source":{"system":"sec-edgar","filing":"0000950170-24-005513","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017024005513/ownership.xml","form_type":"4"}},{"id":1676662,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-18T18:18:45.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":84093,"price":19.65,"value":1652427.45,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":1995958,"source":{"system":"sec-edgar","filing":"0000950170-24-005513","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017024005513/ownership.xml","form_type":"4"}},{"id":1739389,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-16T18:59:54.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":288,"price":16.146,"value":4650.048,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.285, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":393449,"source":{"system":"sec-edgar","filing":"0000950170-23-064611","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023064611/ownership.xml","form_type":"4"}},{"id":1739388,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-16T18:59:54.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":1522,"price":16.146,"value":24574.212,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.285, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2080051,"source":{"system":"sec-edgar","filing":"0000950170-23-064611","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023064611/ownership.xml","form_type":"4"}},{"id":1768045,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T19:13:42.000Z","date":"2023-10-02","kind":"sale","planned":false,"acquired":false,"shares":902,"price":16.07,"value":14495.14,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":393737,"source":{"system":"sec-edgar","filing":"0000950170-23-051728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023051728/ownership.xml","form_type":"4"}},{"id":1768044,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T19:13:42.000Z","date":"2023-10-02","kind":"sale","planned":false,"acquired":false,"shares":4770,"price":16.07,"value":76653.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2081573,"source":{"system":"sec-edgar","filing":"0000950170-23-051728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023051728/ownership.xml","form_type":"4"}},{"id":1768043,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T19:13:42.000Z","date":"2023-09-29","kind":"sale","planned":false,"acquired":false,"shares":15764,"price":16.28,"value":256637.92,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":394639,"source":{"system":"sec-edgar","filing":"0000950170-23-051728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023051728/ownership.xml","form_type":"4"}},{"id":1768042,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T19:13:42.000Z","date":"2023-09-29","kind":"sale","planned":false,"acquired":false,"shares":83337,"price":16.28,"value":1356726.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2086343,"source":{"system":"sec-edgar","filing":"0000950170-23-051728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023051728/ownership.xml","form_type":"4"}},{"id":1771645,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T17:41:08.000Z","date":"2023-09-28","kind":"sale","planned":false,"acquired":false,"shares":1356,"price":16.11,"value":21845.16,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":410403,"source":{"system":"sec-edgar","filing":"0000950170-23-050853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023050853/ownership.xml","form_type":"4"}},{"id":1771644,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T17:41:08.000Z","date":"2023-09-28","kind":"sale","planned":false,"acquired":false,"shares":7160,"price":16.11,"value":115347.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2169680,"source":{"system":"sec-edgar","filing":"0000950170-23-050853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023050853/ownership.xml","form_type":"4"}},{"id":1771643,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T17:41:08.000Z","date":"2023-09-27","kind":"sale","planned":false,"acquired":false,"shares":134,"price":16.07,"value":2153.38,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.14, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":411759,"source":{"system":"sec-edgar","filing":"0000950170-23-050853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023050853/ownership.xml","form_type":"4"}},{"id":1771642,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T17:41:08.000Z","date":"2023-09-27","kind":"sale","planned":false,"acquired":false,"shares":707,"price":16.07,"value":11361.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.14, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2176840,"source":{"system":"sec-edgar","filing":"0000950170-23-050853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023050853/ownership.xml","form_type":"4"}},{"id":1780303,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-15T17:17:35.000Z","date":"2023-09-13","kind":"sale","planned":false,"acquired":false,"shares":64,"price":16,"value":1024.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P.("},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":411893,"source":{"system":"sec-edgar","filing":"0000950170-23-048422","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023048422/ownership.xml","form_type":"4"}},{"id":1780302,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-15T17:17:35.000Z","date":"2023-09-13","kind":"sale","planned":false,"acquired":false,"shares":336,"price":16,"value":5376.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2177547,"source":{"system":"sec-edgar","filing":"0000950170-23-048422","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023048422/ownership.xml","form_type":"4"}},{"id":1784895,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T16:59:56.000Z","date":"2023-09-07","kind":"sale","planned":false,"acquired":false,"shares":537,"price":16.05,"value":8618.85,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P.("},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.25, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":411957,"source":{"system":"sec-edgar","filing":"0000950170-23-047312","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023047312/ownership.xml","form_type":"4"}},{"id":1784894,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T16:59:56.000Z","date":"2023-09-07","kind":"sale","planned":false,"acquired":false,"shares":2841,"price":16.05,"value":45598.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.25, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2177883,"source":{"system":"sec-edgar","filing":"0000950170-23-047312","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023047312/ownership.xml","form_type":"4"}},{"id":1784893,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T16:59:56.000Z","date":"2023-09-06","kind":"sale","planned":false,"acquired":false,"shares":598,"price":16.02,"value":9579.96,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P.("},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.05, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":412494,"source":{"system":"sec-edgar","filing":"0000950170-23-047312","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023047312/ownership.xml","form_type":"4"}},{"id":1784892,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T16:59:56.000Z","date":"2023-09-06","kind":"sale","planned":false,"acquired":false,"shares":3164,"price":16.02,"value":50687.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.05, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2180724,"source":{"system":"sec-edgar","filing":"0000950170-23-047312","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023047312/ownership.xml","form_type":"4"}},{"id":1796563,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-25T16:31:35.000Z","date":"2023-08-23","kind":"sale","planned":false,"acquired":false,"shares":64,"price":16,"value":1024.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":413092,"source":{"system":"sec-edgar","filing":"0000950170-23-044594","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023044594/ownership.xml","form_type":"4"}},{"id":1796562,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-25T16:31:35.000Z","date":"2023-08-23","kind":"sale","planned":false,"acquired":false,"shares":336,"price":16,"value":5376.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2183888,"source":{"system":"sec-edgar","filing":"0000950170-23-044594","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000095017023044594/ownership.xml","form_type":"4"}},{"id":2222229,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-24T17:06:32.000Z","date":"2022-06-06","kind":"other","acquired":true,"shares":26511,"price":15,"value":397665.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\") transferred to Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\") transferred to Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by AGHT Fund DE. The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":413156,"source":{"system":"sec-edgar","filing":"0000899243-22-024050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000089924322024050/doc4.xml","form_type":"4"}},{"id":2222228,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-24T17:06:32.000Z","date":"2022-06-06","kind":"other","acquired":false,"shares":26511,"price":15,"value":397665.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\") transferred to Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\") transferred to Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held directly by AGHT Fund. The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2184224,"source":{"system":"sec-edgar","filing":"0000899243-22-024050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000089924322024050/doc4.xml","form_type":"4"}},{"id":2222227,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2022-06-24T16:51:56.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":74230,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":74230},"source":{"system":"sec-edgar","filing":"0000899243-22-024034","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000089924322024034/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-31"}},{"id":2222226,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2022-06-24T16:51:56.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":392433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":392433},"source":{"system":"sec-edgar","filing":"0000899243-22-024034","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000089924322024034/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-31"}},{"id":2222225,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-06-24T16:51:56.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":312415,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":312415},"source":{"system":"sec-edgar","filing":"0000899243-22-024034","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000089924322024034/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-31"}},{"id":2222224,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-06-24T16:51:56.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":1651636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1651636},"source":{"system":"sec-edgar","filing":"0000899243-22-024034","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000089924322024034/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-31"}},{"id":2222223,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-24T16:51:56.000Z","date":"2022-03-29","kind":"purchase","acquired":true,"shares":166666,"price":15,"value":2499990.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2210735,"source":{"system":"sec-edgar","filing":"0000899243-22-024034","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000089924322024034/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-31"}},{"id":2222222,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-24T16:51:56.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":74230,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":386645,"source":{"system":"sec-edgar","filing":"0000899243-22-024034","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000089924322024034/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-31"}},{"id":2222221,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-24T16:51:56.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":392433,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2044069,"source":{"system":"sec-edgar","filing":"0000899243-22-024034","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000089924322024034/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-31"}},{"id":2222220,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-24T16:51:56.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":312415,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":312415,"source":{"system":"sec-edgar","filing":"0000899243-22-024034","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000089924322024034/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-31"}},{"id":2222219,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":95085,"kind":"organization","name":"Adjuvant Global Health Technology Fund, L.P.","position":1,"cik":"0001783165","reported_name":"Adjuvant Global Health Technology Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95086,"kind":"organization","name":"Adjuvant Global Health Technology Fund DE, L.P.","position":2,"cik":"0001799812","reported_name":"Adjuvant Global Health Technology Fund DE, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95087,"kind":"organization","name":"Adjuvant Capital GP, L.P.","position":3,"cik":"0001935100","reported_name":"Adjuvant Capital GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95088,"kind":"organization","name":"Adjuvant Capital Management, LLC","position":4,"cik":"0001935084","reported_name":"Adjuvant Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-24T16:51:56.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":1651636,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":1651636,"source":{"system":"sec-edgar","filing":"0000899243-22-024034","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935100/000089924322024034/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-31"}}]}